J Khan

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Genomic & proteomic technological advances in cancer research
    Javed Khan
    Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Advanced Technology Center, Room 134E, 8717 Grovemont Circle, Bethesda, MD 20892 4605, USA
    Pharmacogenomics 4:245-9. 2003
  2. pmc Development of peptide nucleic acid probes for detection of the HER2 oncogene
    Belhu Metaferia
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e58870. 2013
  3. pmc Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534)
    Samuel Q Li
    Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e76551. 2013
  4. pmc Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma
    Patricia S Tsang
    Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    BMC Cancer 12:101. 2012
  5. pmc Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status
    Xiang Guo
    Oncogenomics Section, Pediatric Oncology Branch, National Cancer Institute, National Institute of Health, Gaithersburg, MD 20877, USA
    BMC Med Genomics 4:35. 2011
  6. pmc Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen
    Jin Zheng
    Department of Pediatrics, Medical College of Wisconsin and the Children s Research Institute, Children s Hospital of Wisconsin, Milwaukee, WI 53226, USA
    BMC Immunol 8:4. 2007
  7. pmc cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma
    Qing Rong Chen
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
    BMC Genomics 5:70. 2004
  8. pmc Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
    J Khan
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 7:673-9. 2001
  9. ncbi request reprint Analysis of comparative genomic hybridization data on cDNA microarrays
    Sven Bilke
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD, USA
    Methods Mol Biol 377:175-86. 2007
  10. doi request reprint Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor
    Jinesh Gheeya
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD, USA
    Cancer Lett 293:124-31. 2010

Detail Information

Publications50

  1. ncbi request reprint Genomic & proteomic technological advances in cancer research
    Javed Khan
    Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Advanced Technology Center, Room 134E, 8717 Grovemont Circle, Bethesda, MD 20892 4605, USA
    Pharmacogenomics 4:245-9. 2003
  2. pmc Development of peptide nucleic acid probes for detection of the HER2 oncogene
    Belhu Metaferia
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e58870. 2013
    ..4 to 400 fmol for the target gene. The results demonstrate potential application of PNAs as diagnostic probes with high specificity for quantitative measurements of amplifications or over-expressions of oncogenes...
  3. pmc Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534)
    Samuel Q Li
    Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e76551. 2013
    ..Therefore, our data suggests that ponatinib is a potentially effective therapeutic agent for RMS tumors that are driven by a dysregulated FGFR4 signaling pathway...
  4. pmc Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma
    Patricia S Tsang
    Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    BMC Cancer 12:101. 2012
    ..The aim of this study was to identify novel combination chemotherapy to improve survival rate in patients with high-risk neuroblastoma...
  5. pmc Exon array analysis reveals neuroblastoma tumors have distinct alternative splicing patterns according to stage and MYCN amplification status
    Xiang Guo
    Oncogenomics Section, Pediatric Oncology Branch, National Cancer Institute, National Institute of Health, Gaithersburg, MD 20877, USA
    BMC Med Genomics 4:35. 2011
    ..RNA splicing is an important regulatory mechanism of gene expression, and differential RNA splicing may be associated with the clinical behavior of a tumor...
  6. pmc Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen
    Jin Zheng
    Department of Pediatrics, Medical College of Wisconsin and the Children s Research Institute, Children s Hospital of Wisconsin, Milwaukee, WI 53226, USA
    BMC Immunol 8:4. 2007
    ..Serum from mice immunized with our cell-based vaccine in the context of Treg blockade was used to screen a cDNA expression library constructed from the parental neuroblastoma tumor cell line, AGN2a...
  7. pmc cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma
    Qing Rong Chen
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
    BMC Genomics 5:70. 2004
    ..Recurrent non-random genomic alterations are the hallmarks of cancer and the characterization of these imbalances is critical to our understanding of tumorigenesis and cancer progression...
  8. pmc Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
    J Khan
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 7:673-9. 2001
    ..This study demonstrates the potential applications of these methods for tumor diagnosis and the identification of candidate targets for therapy...
  9. ncbi request reprint Analysis of comparative genomic hybridization data on cDNA microarrays
    Sven Bilke
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD, USA
    Methods Mol Biol 377:175-86. 2007
    ..The end result of the analysis is a list of p-values for the presence of genomic gains or losses for each sample individually or an average p-value, which we show is useful to identify recurrent genomic imbalances...
  10. doi request reprint Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor
    Jinesh Gheeya
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD, USA
    Cancer Lett 293:124-31. 2010
    ..Our study indicates that Epoxy anthraquinone derivative may be a novel DNA topoisomerase inhibitor that can be potentially used for treatment of neuroblastoma or other cancer patients...
  11. pmc Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification
    Sven Bilke
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, Maryland, USA
    Clin Cancer Res 14:5540-7. 2008
    ..The goal of this study is to develop a DNA copy number-based prognostic profile for these patients...
  12. pmc Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth
    C L Yeung
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Oncogene 32:5429-38. 2013
    ..This study also demonstrates the use of functional screening to identify a potentially novel therapeutic target and treatment approach for these highly aggressive pediatric cancers. ..
  13. pmc CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression
    Z Liu
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Cell Death Differ 18:1174-83. 2011
    ..These data are consistent with CASZ1 being a critical modulator of neural cell development, and that somatically acquired disruption of normal CASZ1 expression contributes to the malignant phenotype of human NB...
  14. pmc BBC3 mediates fenretinide-induced cell death in neuroblastoma
    Jun S Wei
    Pediatric Oncology Branch, National Cancer Institute, 8717 Grovemont Circle, Bethesda, MD 20892 4605, USA
    Oncogene 24:7976-83. 2005
    ..Our results indicate that BBC3 mediates cell death in NB cells in response to 4-HPR...
  15. ncbi request reprint Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers
    Amir A Jazaeri
    Laboratory of Biosystems and Cancer, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:6300-10. 2005
    ..The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in epithelial ovarian carcinoma...
  16. ncbi request reprint Increased WSB1 copy number correlates with its over-expression which associates with increased survival in neuroblastoma
    Qing Rong Chen
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
    Genes Chromosomes Cancer 45:856-62. 2006
    ..This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat...
  17. ncbi request reprint High-resolution cDNA microarray-based comparative genomic hybridization analysis in neuroblastoma
    Qing Rong Chen
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, 8717 Government Circle, Gaithersburg, MD 20877, USA
    Cancer Lett 228:71-81. 2005
    ..We also discuss hypothetic evolutionary models of neuroblastoma progression that can be derived from A-CGH data...
  18. ncbi request reprint Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis
    Craig C Whiteford
    Oncogenomics Section, Comparative Oncology Program, and Cell and Molecular Biology Section, Pediatric Oncology Branch
    Cancer Res 67:32-40. 2007
    ..The database will facilitate the identification of tumor markers predictive of response to tested agents as well as the discovery of new molecular targets...
  19. pmc Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells
    Patrick J Grohar
    Molecular Oncology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1928, USA
    Neoplasia 13:145-53. 2011
    ..In addition, the modulation of EWS-FLI1 makes it a novel targeting agent for ESFT and suggests that further development of this compound for the treatment of ESFT is warranted...
  20. pmc microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies
    Jun S Wei
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, Maryland 20877, USA
    Clin Cancer Res 15:5560-8. 2009
    ..We therefore have performed expression profiles on a panel of pediatric tumors to identify cancer-specific microRNAs. We also investigated if microRNAs are coregulated with their host gene...
  21. ncbi request reprint Proceedings: the Applications of Bioinformatics in Cancer Detection Workshop
    Izet M Kapetanovic
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7322, USA
    Ann N Y Acad Sci 1020:1-9. 2004
    ..This paper summarizes the proceedings of this conference and points out future directions for research...
  22. ncbi request reprint Gene expression profiling in cancer using cDNA microarrays
    Javed Khan
    Oncogenomics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Med 68:205-22. 2002
  23. ncbi request reprint Detection of low level genomic alterations by comparative genomic hybridization based on cDNA micro-arrays
    Sven Bilke
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
    Bioinformatics 21:1138-45. 2005
    ..However, when detecting low-level DNA copy number changes this technology requires the use of noise reduction strategies due to a low signal to noise ratio...
  24. ncbi request reprint Tumor classification using phylogenetic methods on expression data
    Richard Desper
    National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Department of Health and Human Services, Bldg 38A, Room 8N805, 8600 Rockville Pike, Bethesda, MD 20894, USA
    J Theor Biol 228:477-96. 2004
    ..We tested this method on the SRBCT data set, and classified each tumor successfully...
  25. ncbi request reprint Analyzing array data using supervised methods
    Markus Ringner
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Building 50, Room 5142, 50 South Drive MSC 8000, Bethesda, MD 20892, USA
    Pharmacogenomics 3:403-15. 2002
    ..Here, methods with special reference to applications for pharmacogenomics are reviewed...
  26. ncbi request reprint Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease
    Roberto Bomprezzi
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Bldg 50 Room 5150, Bethesda, MD 20892 8000, USA
    Hum Mol Genet 12:2191-9. 2003
    ....
  27. pmc The MYCN oncogene is a direct target of miR-34a
    J S Wei
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD 20892, USA
    Oncogene 27:5204-13. 2008
    ..This study demonstrates one important regulatory role of miR-34a in cell growth and MYCN suppression in neuroblastoma...
  28. pmc An integrated cross-platform prognosis study on neuroblastoma patients
    Qing Rong Chen
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD 20877, USA
    Genomics 92:195-203. 2008
    ..Our study showed that gene expression studies performed in different platforms could be integrated for prognosis analysis after removing variation resulting from different platforms...
  29. pmc Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma
    Qing Rong Chen
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, Maryland 20877, USA
    J Proteome Res 9:373-82. 2010
    ..We used global genomic and proteomic analysis to identify biologically relevant proteins and pathways important to NB progression and development that may provide new insights into the biology of advanced neuroblastoma...
  30. ncbi request reprint Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators
    Yanlin Yu
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 10:175-81. 2004
    ..The identification of ezrin and Six-1 as critical regulators of metastasis in RMS provides new mechanistic and therapeutic insights into this pediatric cancer...
  31. ncbi request reprint Altered expression of cell cycle genes distinguishes aggressive neuroblastoma
    Alexei L Krasnoselsky
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
    Oncogene 24:1533-41. 2005
    ..Finally, we establish that these genes are further upregulated in the most aggressive MYCN-amplified tumors...
  32. ncbi request reprint Metastasis-associated differences in gene expression in a murine model of osteosarcoma
    C Khanna
    Pediatric Oncology, National Cancer Institute, and Cancer Genetics Branch, Human Genome Research Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:3750-9. 2001
    ..This work represents a rationale approach to the evaluation of microarray data and will be useful to identify genes that may be causally associated with metastasis...
  33. pmc Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma
    Jun S Wei
    Advanced Technology Center, Oncogenomics Section, Pediatric Oncology Branch, National Cancer Institute, NIH, Gaithersburg, Maryland 20877, USA
    Cancer Res 64:6883-91. 2004
    ..0005). Our findings provide evidence of a gene expression signature that can predict prognosis independent of currently known risk factors and could assist physicians in the individual management of patients with high-risk neuroblastoma...
  34. ncbi request reprint Diagnostic classification of cancer using DNA microarrays and artificial intelligence
    Braden T Greer
    Advanced Technology Center, National Cancer Institute, National Institutes of Health, Gaithersburg, MD 20877, USA
    Ann N Y Acad Sci 1020:49-66. 2004
    ..Several such applications are summarized in this chapter, and some of the common pitfalls are noted...
  35. ncbi request reprint Online analysis of microarray data using artificial neural networks
    Braden Greer
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD, USA
    Methods Mol Biol 377:61-74. 2007
    ..This is one possible method of many but we have found it suitable to microarray data and attempted to discuss universal guidelines for this type of analysis along the way...
  36. pmc Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma
    Jinesh S Gheeya
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD, USA
    Cancer Biol Ther 8:2386-95. 2009
    ..These drugs thus represent potential novel therapeutic agents for patients with NB, and further validation studies are needed to translate them to the clinic...
  37. ncbi request reprint Inferring a tumor progression model for neuroblastoma from genomic data
    Sven Bilke
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD, USA
    J Clin Oncol 23:7322-31. 2005
    ....
  38. pmc Database of mRNA gene expression profiles of multiple human organs
    Chang Gue Son
    Advanced Technology Center, Oncogenomics Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Gaithersburg, Maryland 20877, USA
    Genome Res 15:443-50. 2005
    ..We expect this database will be of utility for developing rationally designed molecularly targeted therapeutics in diseases such as cancer, as well as for exploring the functions of genes...
  39. ncbi request reprint Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis
    J Dupont
    Section on Cellular and Molecular Physiology, Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 208952-1758, USA
    Endocrinology 142:4969-75. 2001
    ..Our results indicate that under the conditions used in this study, IGF-1 is a more potent activator of the mitogenic pathway than insulin in mouse fibroblast NIH-3T3 cells...
  40. pmc Expression of genes encoding innate host defense molecules in normal human monocytes in response to Candida albicans
    Hee Sup Kim
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute NIH, Room 1 5740, Bethesda, MD 20892, USA
    Infect Immun 73:3714-24. 2005
    ..albicans. Thus, C. albicans is a potent inducer of a dynamic cascade of expression of genes whose products are related to the recruitment, activation, and protection of neutrophils and monocytes...
  41. pmc Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models
    James G Taylor
    Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute NHLBI, NIH, Bethesda, Maryland 20892 4605, USA
    J Clin Invest 119:3395-407. 2009
    ..These findings support the potential therapeutic targeting of FGFR4 in RMS...
  42. pmc Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction
    Qing Rong Chen
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
    J Mol Diagn 9:80-8. 2007
    ..Our results suggest that this molecular test based on a multiplex PCR reaction may assist the physician in the rapid confirmation of the diagnosis of these cancers...
  43. ncbi request reprint Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines
    Richard D Williams
    Section of Paediatric Oncology, Institute of Cancer Research, Sutton, Surrey, UK
    Genes Chromosomes Cancer 41:65-79. 2004
    ..This set of discriminators was highly enriched in genes on 1q, indicating close agreement between data obtained from expression profiling with data from genomic copy number analyses...
  44. doi request reprint Molecular characterization of the pediatric preclinical testing panel
    Geoffrey Neale
    Hartwell Center of Bioinformatics and Biotechnology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 14:4572-83. 2008
    ..Identifying novel therapeutic agents for the treatment of childhood cancers requires preclinical models that recapitulate the molecular characteristics of their respective clinical histotypes...
  45. ncbi request reprint High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status
    Frank Westermann
    Department of Tumor Genetics, German Cancer Research Center, Heidelberg, Germany
    Clin Cancer Res 13:4695-703. 2007
    ..However, a substantial number of MYCN single-copy neuroblastomas exhibits an aggressive phenotype similar to that of MYCN-amplified neuroblastomas even in the absence of high MYCN mRNA and/or protein levels...
  46. ncbi request reprint The pediatric preclinical testing program: description of models and early testing results
    Peter J Houghton
    Department of Molecular Pharmacology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 49:928-40. 2007
    ..Here, we describe the characteristics of the in vivo tumor panels and report results for the in vivo evaluation of two standard agents, vincristine and cyclophosphamide...
  47. pmc Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO
    Jennifer L Alabran
    Department of Pediatrics, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Cancer Biol Ther 7:709-17. 2008
    ..These data demonstrate the potential utility of CDDO analogs as promising novel therapeutic agents for high-risk pediatric solid tumors...
  48. ncbi request reprint Cyclooxygenase-2 expression in pediatric sarcomas
    David S Dickens
    Department of Pediatrics, Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Pediatr Dev Pathol 5:356-64. 2002
    ..We conclude that the majority of these pediatric sarcoma samples express COX-2 to varying degrees. Therefore, studies testing the efficacy of COX-2 inhibitors in the treatment of pediatric sarcomas are warranted...
  49. ncbi request reprint Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients
    Kai Oliver Henrich
    Department of Tumour Genetics B030, Molecular Genetics B060, Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Clin Cancer Res 12:131-8. 2006
    ..A 1p36.3 commonly deleted region, bordered by D1S2731 and D1S214 has been defined. The present study surveys whether expression of genes mapping to this region is associated with tumor behavior...
  50. ncbi request reprint Gene expression profiles that segregate patients with childhood acute lymphoblastic leukaemia: an independent validation study identifies that endoglin associates with patient outcome
    Daniel Catchpoole
    The Tumour Bank, The Oncology Research Unit, The Children s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia
    Leuk Res 31:1741-7. 2007
    ..An artificial neural network identified endoglin, which was reported in the initial study as a potential lineage marker, was actually better at identifying ALL patients with poor outcome...